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The Society for Vascular Surgery pursued development of clinical practice guidelines for the management of the left
subclavian artery with thoracic endovascular aortic repair (TEVAR). In formulating clinical practice guidelines, the
society selected a panel of experts and conducted a systematic review and meta-analysis of the literature. They used the
grading of recommendations assessment, development, and evaluation (GRADE) method to develop and present their
recommendations. The overall quality of evidence was very low. The committee issued three recommendations.
Recommendation 1: In patients who need elective TEVAR where achievement of a proximal seal necessitates coverage of
the left subclavian artery, we suggest routine preoperative revascularization, despite the very low-quality evidence
(GRADE 2, level C).Recommendation 2: In selected patients who have an anatomy that compromises perfusion to critical
organs, routine preoperative LSA revascularization is strongly recommended, despite the very low-quality evidence
(GRADE 1, level C).Recommendation 3: In patients who need urgent TEVAR for life-threatening acute aortic syndromes
where achievement of a proximal seal necessitates coverage of the left subclavian artery, we suggest that revascularization
should be individualized and addressed expectantly on the basis of anatomy, urgency, and availability of surgical expertise
(GRADE 2, level C). (J Vasc Surg 2009;50:1155-8.)Thoracic endovascular aortic repair (TEVAR) is a rap-
idly evolving new therapy in the treatment of thoracic
aneurysms and dissections. TEVAR involves placing an
endovascular stent graft into the thoracic aorta from a
remote peripheral location under imaging guidance. Be-
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doi:10.1016/j.jvs.2009.08.090cause it is less invasive than traditional thoracotomy with
direct operative repair, TEVAR has the potential to revolu-
tionize the treatment of thoracic aneurysms, similar to the
development of prosthetic grafts for open repair.
Reports of patients with large thoracic aneurysms (6
cm in diameter) show an annual risk of rupture that varies
from 10% to 15%, and 90% of these patients do not
survive if the aneurysm ruptures.1,2 Over the years, sur-
geons have developed successful techniques to significantly
decrease major complications associated with open surgical
repair of thoracic aneurysms.3-6 Although these contribu-
tions have resulted in vast improvements in the care of
patients with thoracic aneurysms, open repair is still associ-
ated with considerable morbidity and mortality. This has
led physicians to seek less invasive methods of treat-
ment.7-12 TEVAR offers potential for durable aneurysm
exclusion while avoiding thoracotomy and aortic cross-
clamping. Nevertheless, stroke, spinal cord ischemia, and
other complications that are associated with open repair can
also occur with TEVAR.
Up 40% of patients undergoing TEVAR have pathol-
ogy that extends near the left subclavian artery (LSA).8 In
these situations, currently approved devices are typically
placed over the LSA origin, thereby occluding this arch
vessel. Some surgeons routinely performLSA revasculariza-
tion in these patients, whereas others do in certain circum-
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artery (60% of patients), a previous left internal mammary
coronary artery bypass graft, or the distal right vertebral
segment is absent. Finally, some surgeons do not perform
LSA revascularization when this artery is covered unless
symptoms develop after TEVAR.11-17 Published reports
show the baseline risks of adverse outcomes in patients who
have TEVAR and LSA coverage are 6% arm ischemia, 4%
spinal cord ischemia, 2% vertebrobasilar ischemia, 5% ante-
rior circulation stroke, and 6% death.18 Treatments that
reduce these risks are important to characterize.
The Society for Vascular Surgery identified several key
issues that require the development of clinical practice
guidelines to aid surgeons, referring physicians, and pa-
tients in the process of decision making. LSA revasculariza-
tion was one of these areas. In developing these guidelines,
the society used similar processes and format to its recently
published guidelines:
First, the society selected a committee of experts in the
field with knowledge of clinical aspects as well as patients’
values and preferences in this regard.
Second, the society commissioned the Knowledge and
Encounter Research Unit, Mayo Clinic, Rochester, a third
party with expertise in evidence-based medicine, knowl-
edge synthesis, and guideline development to conduct a
comprehensive systematic review of the literature and iden-
tify the best available evidence. The society acknowledged
the value of systematic reviews and meta-analyses because,
compared with individual studies, they provide evidence
that is more precise and more likely to be applicable to a
wider range of patients.
Third, the society used the grading of recommenda-
tions assessment, development, and evaluation (GRADE)
methods to develop and present its recommendations. The
GRADEmethod provides superior clarity and separates the
quality of evidence from the strength of recommendations
and allows for the inclusion of patients’ values and prefer-
ences in recommendations. The GRADE system depicts
recommendations as either strong (GRADE 1), denoted by
the phrase “we recommend,” or weak (GRADE 2), de-
noted by the phrase “we suggest.” Aside from the strength
of recommendations, the quality of evidence is graded as
high quality (level A, typically derived from well conducted
randomized trials), moderate quality (level B, typically de-
rived from less rigorous or inconsistent randomized trials),
and low or very low quality (level C, derived from observa-
tional studies, case series, and unsystematic observations or
expert opinion). See the Table.19
In this article, the Committee on Aortic Disease pre-
sents three recommendations with the aim of clarifying the
role of LSA revascularization. Although there is significant
diversity of individual opinions, the report reflects the
consensus of the committee. The recommendations are
followed by the supporting evidence, values statement, and
relevant technical remarks. A detailed description of the
data analysis is in the accompanying article.18RECOMMENDATIONS
Prospective randomized trials directly comparing a selec-
tive strategy of LSA revascularization and routine LSA revas-
cularization as well as other techniques of neuroprotection are
unavailable and are needed. The following recommendations
are based on systematic review of the literature:
● Recommendation 1: In patients who need elective
TEVAR where achievement of a proximal seal neces-
sitates coverage of the LSA, we suggest routine preop-
erative revascularization despite the very low-quality
evidence (GRADE 2, level C).
● Recommendation 2: In selected patients who have an
anatomy that compromises perfusion to critical or-
gans, routine preoperative LSA revascularization is
strongly recommended despite the very low-quality
evidence (GRADE 1, level C).
● Recommendation 3: In patients who need very urgent
TEVAR for life-threatening acute aortic syndromes
where achievement of a proximal seal necessitates cover-
age of the LSA, we suggest that revascularization should
be individualized and addressed expectantly on the basis
of anatomy, urgency, and availability of surgical expertise
(GRADE 2, level C).
EVIDENCE
The systematic review commissioned by the society
demonstrated that the coverage of the LSA artery is associ-
ated with a trend towards an increase in the risk of paraple-
gia (odds ratio [OR], 2.69; 95% confidence interval [CI],
0.75-9.68) and anterior circulation stroke (OR, 2.58; 95%
CI, 0.82-8.09), and a significant increase in the risk of arm
ischemia (OR, 47.7; 95% CI, 9.9-229.3) and vertebrobasi-
lar ischemia (OR, 10.8; 95% CI, 3.17-36.7).18 The inci-
dence of phrenic nerve injury as a complication of primary
revascularization was a modest 4.40% (95% CI, 1.60%-
12.20%). There was no association with death, myocardial
infarction, or transient ischemic attack.
Statistical analysis in this review was robust to sensitivity
analysis, and meta-analysis was conducted using the random-
effects model, which yields conservative estimates. No sig-
Table. Recommendations according to the grading of
recommendations assessment, development, and
evaluation (GRADE) system19
The GRADE system categorizes recommendations as
● strong (GRADE 1) denoted by the phrase “we recommend,”
or
● weak (GRADE 2) denoted by the phrase “we suggest.”
The quality of evidence is graded as
● high-quality (level A), typically derived from well conducted
randomized trials,
● moderate-quality (level B), typically derived from less rigorous
or inconsistent randomized trials,
● low- or very-low quality, (level C), derived from observational
studies, case series, and unsystematic observations or expert
opinion.nificant subgroup interactions were noted by indication
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tests for subgroup interaction based on the control group
in these studies showed no significant interaction for all
outcomes except arm ischemia, suggesting that the magni-
tude of increased risk of arm ischemia due to LSA coverage
was greater when coverage was compared with no coverage
than when coverage was compared with coverage preceded
by primary revascularization.
Several limitations of the literature review deserve com-
ment, because the quality of the evidence was very low.
Reporting is not consistent or uniform for potentially rele-
vant confounding factors. Including patency of the verte-
bral arteries, definitions of hand ischemia, wound compli-
cations such as lymphatic leaks, handedness of the patients,
presence of reconstructive procedures distal to the LSA
origin, and abnormal arch anatomy.20
The evidence supporting TEVAR compared with open
repair appears to be associated with lower postoperative
mortality and ischemic spinal cord complication rates for
patients with traumatic aortic injury. Meta-analysis of ret-
rospective cohort studies demonstrated that endoluminal
repair was associated with lower procedurally related mor-
tality (OR, 0.31; 95% CI, 0.15-0.66; P  .002), overall
30-day mortality (OR, 0.44; 95% CI, 0.25-0.78; P 
.005), and postoperative paraplegia (OR, 0.32; 95% CI,
0.1-0.93; P  .037). The quality of evidence was also very
low in this context.21
VALUES STATEMENT
Neurologic events, including stroke and paraplegia, are
critical clinical concerns when descending thoracic aneurysm
repair is considered. These well-recognized complications oc-
cur after open surgical repair and TEVAR, and often lead to
the eventual deathof the patient.7,10Theguideline developers
placed a relatively higher value on preventing these cata-
strophic complications and a relatively lower value on less
devastating perioperative complications of LSA revasculariza-
tion. They also placed a relatively high value on avoiding
stroke andparaplegia in the clinical context of decisionmaking
with very low-quality evidence, but tempered the strength of
the recommendation because of the quality of the evidence.
The role of these values was particularly emphasized in the
case of selected patients who have an anatomy that compro-
mises perfusion to critical organs. In this case, the committee
made a stronger recommendation, despite the paucity of
evidence, to prevent these complications.
TECHNICAL REMARKS
The LSA is the primary artery to the left arm and a
source of blood flow to the brain and spinal cord. Brain and
spinal cord perfusion is particularly relevant when collateral
pathways are compromised. In addition, many anatomic
situations (discussed below) effectively mandate preserva-
tion of antegrade LSA blood flow to avoid a potentially
catastrophic outcome.
Neurologic injury with TEVAR. Themechanisms of
neurologic injury are multifactorial with TEVAR. Stroke
may be caused by (1) systemic factors such as hypotension,hypertension, and anticoagulation; (2) intracranial changes
related to edema, cerebrospinal fluid drainage, or contrast/
drug infusion; (3) embolization of air, atheroma, or throm-
bus from the device or manipulation of devices within the
aortic arch; and (4) interruption of forward blood flow
from injury or coverage of arch vessels.
The LSA provides blood flow to the upper spinal cord
through the vertebral artery to the anterior spinal artery,
and collateral perfusion to the left intercostal vessels
through the thoracodorsal and other chest wall branch
arteries. Paraplegia may be caused by (1) systemic factors
such as hypotension, drug-induced vasoconstriction, and
embolization; (2) local factors, including intraspinal hema-
toma, injury due to spinal cord drain placement, and (3)
lack of blood flow caused by coverage of intercostal, lum-
bar, middle sacral, hypogastric, or subclavian arteries. Spi-
nal cord damage after TEVAR may cause complete or
partial neurologic deficit. The onset of symptoms can be
immediate or delayed, and in some cases the deficit can
improve.7,10-11
Arm ischemia and vertebrobasilar ischemia with
TEVAR. The LSA normally provides antegrade blood
flow to the left vertebral artery and ipsilateral arm. When
the LSA origin is acutely occluded, patients may experience
left arm ischemia due to inadequate collateral perfusion.
Symptoms may exacerbate when the patients exercise the
ipsilateral upper extremity. Flow reversal in the left vertebral
artery may also occur, resulting in steal of blood from the
posterior circulation. At times this can cause a full-blown
vertebral steal phenomenon with vertebrobasilar ischemic
symptoms manifested as syncope, diplopia, or vertigo. In
contrast to stroke and paraplegia, arm and vertebrobasilar
ischemia may be addressed on a more elective basis.
LSA REPAIR TECHNIQUES
Traditional LSA revascularization in the setting of
chronic occlusive disease has been performed with transpo-
sition of the artery to the left common carotid artery or a
short bypass originating from the left common carotid
artery. In the setting of TEVAR, the technique has evolved
to encompass a short bypass from the left common carotid
artery to the LSA as well as proximal subclavian ligation or
embolization to prevent type II endoleak. Potential com-
plications include stroke, bleeding, and injury to the tho-
racic duct and left neck nerves, including the phrenic,
vagus, sympathetic chain, and brachial plexus. Most nerve
injuries are temporary, and only a few are permanent. LSA to
carotid transposition may carry lower risk of phrenic nerve
injury and does not require use of prosthetic material.14,15
Left carotid to subclavian bypass should be selected when
there is an internal mammary artery to coronary artery bypass
graft because it allows continuous antegrade perfusion of the
coronary artery. Some surgeons prefer the bypass option be-
cause it avoids the less familiar medial dissection around the
thoracic duct and allows access to the left carotid and LSA
from a left brachial approach. Pneumothorax, prosthetic graft
infection, and late occlusion are rare after these procedures.
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occlusive disease have not been published.
In selected patients who have an anatomy that compro-
mises perfusion to the brain, spinal cord, heart, or left arm,
routine preoperative LSA revascularization is strongly rec-
ommended. Some of these conditions are:
● presence of a patent left internal mammary artery to
coronary artery bypass graft,
● termination of the left vertebral artery at the posterior
inferior cerebellar artery or other discontinuity of the
vertebrobasilar collaterals,
● absent or diminutive or occluded right vertebral artery,
● a functioning arteriovenous shunt in the left arm,
● prior infrarenal aortic repair with ligation of lumbar
and middle sacral arteries,
● planned long-segment (20 cm) coverage of the de-
scending thoracic aorta where critical intercostal arter-
ies originate,
● hypogastric artery occlusion, and
● presence of early aneurysmal changes that may require
subsequent therapy involving the distal thoracic aorta.
The increased risk of complications with each of these
conditions is not precisely defined in the literature, but
these high-risk conditions are ranked by the strength of
consensus of guideline developers.
In many circumstances, individualized care must be
tailored using clinical judgment. Routine LSA revascular-
ization may not be possible in some patients in whom acute
ischemia or hemorrhage requires immediate TEVAR or
where local surgical expertise is not available. LSA revascu-
larization can then be considered selectively soon after
TEVAR or in a staged approach if symptoms develop. A few
patients may have anatomy that makes LSA revasculariza-
tion difficult, such as previous local operation and scarring
or previous radiation treatment. Congenital anomalies such
as aberrant arch anatomy or abnormalities of the LSA or
vertebral arteries may hinder revascularization of the LSA.
CONCLUSION
Although the quality of evidence is very low, preoperative
LSA revascularization is suggested in patients undergoing
TEVARwith coverage of the LSA. Preoperative LSA revascu-
larization is strongly recommended in selected patients with
compromised collateral circulation. Exceptions include emer-
gency TEVAR where there is no time for LSA revasculariza-
tion, when anatomic circumstances preclude LSA revascular-
ization, or when expertise in the procedure is not available.
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